Germany approved 32 new cannabis import partnerships with Canadian Licensed Producers between January and December 2025, according to BfArM filings. The pace has accelerated again in 2026. For international buyers evaluating which Canadian LP to sign with, the supplier shortlist now matters more than the country of origin. Canada has 158 licensed cultivators. Roughly 40 are export-ready. Maybe a dozen consistently ship pharmaceutical-grade product. The gap between those tiers is the entire story.
This guide is written for the procurement managers, pharmacy distributors, and import licence holders in Germany, Australia, and Israel who are past the introductory call stage and now need a defensible vetting process. We will name what to ask, what to verify, and where most LPs fail the audit.
What "export-ready" actually means in 2026
An export-ready Canadian LP holds four overlapping authorisations. The federal cultivation and processing licence comes from Health Canada under the Cannabis Act. The export permit is issued per-shipment by the same regulator under the Cannabis Regulations. A EU-GMP certificate, where required for the destination market, comes from an EU competent authority after a site audit. And the testing layer requires a lab operating under ISO 17025 accreditation.
Most procurement teams stall on the second tier. The federal licence is straightforward to verify. The export permit is shipment-specific, so it appears late in the process. The EU-GMP certificate is where things get genuinely difficult, because not every Canadian LP that claims pharmaceutical readiness actually carries the certification on paper. Ask for the certificate number. Ask which issuing authority. If you get hedging, you have your answer.
The 4-Criteria LP Vetting Framework
Use these four criteria in this order. Each one filters out a different category of risk. By the time a supplier clears all four, you have a defensible shortlist.
| Criterion | What to verify | How to verify it |
|---|---|---|
| 1. Federal authorisation | Active cultivation, processing, and sales-for-medical licences | Health Canada Licensed Producer registry, current status |
| 2. Export history | Shipment count and destination markets in the last 24 months | Reference letters from named importers, customs records on request |
| 3. EU-GMP or equivalent | Active certificate from a recognised competent authority | Certificate number, issuing body, EudraGMDP database entry |
| 4. Batch documentation depth | Full COA panel, retention samples, deviation reports, recall capability | Sample COA pack for a recent batch, audit visit if scale justifies it |
The criteria are sequential. There is no value in inspecting batch documentation from a supplier who cannot prove export history. Most rejections happen at criteria two and three. The fourth is where serious buyers separate qualified suppliers from preferred ones.
Where the vetting actually breaks down
Most LPs stall at batch documentation. Not because the rules are unclear. Because Health Canada and BfArM want different things from the same paperwork, and a producer who has only ever served the Canadian medical channel has never been pushed to reconcile both. The Canadian COA gives you potency, microbial, heavy metals, pesticides, residual solvents, and water activity. A pharmaceutical-grade German import file expects all of that plus stability data, batch-specific shelf-life justification, and process validation documentation that ties the COA back to a documented manufacturing process.
The friction is rarely a missing test. It is the inability to produce the surrounding documentation that proves the test was run on this batch, under controlled conditions, by a qualified person. Ask any LP for their batch release procedure and the qualified person designation. Ask to see a redacted example. The speed of the response is diagnostic.
Small LPs without a dedicated regulatory affairs team should not attempt German export yet. The documentation load is real, the audit pressure is constant, and a single deviation report mishandled at the wrong time can cost you a year of remediation.
The questions that separate serious suppliers from hopeful ones
Procurement teams who are new to the Canadian market often run a generic supplier questionnaire. The result is technically complete and operationally useless. The questions below are the ones that surface real information.
- How many discrete export shipments have you completed in the last 24 months, by destination country?
- Which competent authority issued your most recent EU-GMP certificate, and when does it expire?
- What is your average lead time from purchase order to customs clearance at destination?
- Who is your designated qualified person, and what are their credentials?
- Walk me through your last batch deviation. What happened, what was the root cause, and what changed afterward?
- Can you provide reference contact details for two current European or Australian customers?
The deviation question is the most useful one on the list. A supplier with mature quality systems will answer it directly, name the deviation, describe the corrective action, and move on. A supplier without those systems will either claim no deviations have occurred or describe the process in abstract terms. Both responses are signals.
Timing the audit visit
An on-site audit is the most informative single step in the vetting process. It is also the most expensive. The right time to schedule one is after the supplier has cleared criteria one through three on paper, and before you sign a multi-shipment purchase agreement. Earlier is wasted money. Later means you have already signed.
Plan for two days minimum at the facility. One day on cultivation and processing flow. One day on quality systems, document review, and batch traceability. Bring a Qualified Person from your own organisation or a contracted EU-GMP auditor. The audit checklist should map directly to the requirements of your destination market regulator, not a generic GMP template. A German importer auditing a Canadian LP against US cGMP standards will miss the things that actually matter at BfArM.
Why Canadian origin still carries weight
The Canadian regulatory framework is one of the most demanding cannabis production environments in the world. Every gram produced by a federal Licensee is tracked from seed through sale. Lab testing is mandatory on every batch, not every shipment. Health Canada conducts unannounced inspections. The federal export permit process requires destination authority sign-off before product leaves the country.
That regulatory depth is the reason German pharmacy distributors, Australian medical channel buyers, and Israeli importers continue to favour Canadian-origin product even as European cultivation capacity expands. The standards have been stress-tested across a decade of medical and adult-use supply. The systems are mature. The audit trail is real.
AlphaLeaf is a Health Canada Licensed Producer based in Montreal, supplying premium hand-trimmed dried flower to international medical channels. Our facility operates under ISO 17025 accredited testing, full batch traceability from cultivation through export, and active authorisation for shipment to German, Australian, and Israeli partners. We work primarily with importers and distributors who require pharmaceutical-grade documentation and consistent batch performance across multi-shipment supply agreements.
Frequently Asked Questions
How long does it take to qualify a new Canadian cannabis supplier for export?
From first contact to first shipment, expect 12 to 20 weeks for a buyer with mature procurement systems. The bottleneck is rarely the supplier side. It is the destination-market import permit, the EU-GMP audit cycle if required, and the customs documentation review on the first shipment. After the initial shipment, subsequent orders typically clear within four to six weeks.
What is the difference between Health Canada GMP and EU-GMP for cannabis?
Health Canada operates under the Good Production Practices framework in the Cannabis Regulations, which governs Canadian medical and adult-use production. EU-GMP is a pharmaceutical standard maintained by European competent authorities and is required for cannabis product sold through pharmacy channels in Germany and several other European markets. The two frameworks overlap substantially but are not interchangeable. A Canadian LP holding only the federal licence cannot ship to German pharmacy without EU-GMP certification on top.
Does AlphaLeaf hold EU-GMP certification?
AlphaLeaf operates under Health Canada Good Production Practices with active export authorisation. International buyers can request current certification status and audit history directly from our compliance team. Certification status is reviewed and updated as part of standard partner onboarding.
How many Canadian LPs are actively exporting cannabis in 2026?
Roughly 40 federally licensed producers hold active export authorisation, but the consistently active exporters number closer to a dozen. Active export status requires an export permit application per shipment, so the published Health Canada figures reflect cumulative authorisation rather than current shipping volume. Reference checks with named importers are the most reliable way to confirm a producer's actual export track record.
What documentation should accompany a first shipment from a Canadian LP?
At minimum: the Health Canada export permit specific to the shipment, the destination country import permit, a full certificate of analysis for the batch with all required panels for the destination market, the phytosanitary certificate from the Canadian Food Inspection Agency, commercial invoice and packing list, and the qualified person batch release statement. Missing or incomplete documentation on first shipment is the single most common cause of customs holds at destination.
Building a supplier shortlist that holds up
The Canadian supplier base is wider than the export-capable subset. The export-capable subset is wider than the pharmaceutical-grade subset. Most procurement failures happen because buyers do not separate the three. Run the four-criteria framework. Ask the deviation question. Schedule the audit at the right point in the cycle. Verify EU-GMP through EudraGMDP rather than supplier-supplied PDFs.
The market is there. The demand is real. The question is whether your vetting process can keep up. Connect with our international team if you are evaluating Canadian LP partners for a 2026 supply agreement, or review our certification documentation and current product catalogue before scheduling an introductory call. For pharmaceutical distributors with active import licences, our compliance team can walk through specific destination-market documentation requirements.
